登录
Intermittent suppressive posaconazole therapy is ineffective at mitigating cardiac and digestive tract pathologies in an experimental model of chronic Chagas disease [0.03%] 间歇性抑制泊沙康唑治疗不能缓解慢性查加斯病实验模型的心脏和消化道病变
Shiromani Jayawardhana,Francisco Olmo,Amanda Fortes Francisco et al. Shiromani Jayawardhana et al.
Infections with Trypanosoma cruzi cause Chagas disease, a chronic condition that can give rise to debilitating cardiac and/or gastrointestinal damage. However, it is unclear why only ~30% of individuals progress to symptomatic pathology, wh...
Antimicrobial susceptibility and genetic mechanisms of resistance of Ureaplasma isolates in North America between 2012 and 2023 [0.03%] 2012年至2023年北美洲脲原体分离株的抗微生物敏感性及耐药遗传机制
Joshua T Waites,Donna M Crabb,Amy E Ratliff et al. Joshua T Waites et al.
We analyzed antimicrobial susceptibilities of 415 Ureaplasma isolates from various sample types derived from different regions of the United States and Canada from 2012 to 2023 and investigated the genetic mechanisms of antimicrobial resist...
Regulation of phosphatidylinositol-(4,5)-bisphosphate and active-Rho1p levels and distribution is crucial for correct spatio-temporal cytokinesis and echinocandin responses in Candida albicans [0.03%] 白色念珠菌中磷脂酰肌醇-（4,5）-双磷酸和活化Rho1的调节，水平和分布对于正确的时空细胞分裂和棘白菌素反应至关重要
Hassan Badrane,M Hong Nguyen,Cornelius J Clancy Hassan Badrane
Candida species cause severe infections like invasive candidiasis, which annually affects 1.5 million people worldwide and causes close to 1 million deaths. Candida albicans is the predominant cause of candidiasis. We previously showed that...
Ex vivo assessment and simulation to guide cefepime-taniborbactam dosing recommendations for patients receiving continuous renal replacement therapy [0.03%] 体外评估和模拟指导连续肾脏替代治疗患者的哌拉西林/他唑巴坦剂量推荐
Aliaa Fouad,Cole McGrath,Ecem Buyukyanbolu et al. Aliaa Fouad et al.
Cefepime-taniborbactam dosing in patients undergoing continuous renal replacement therapy (CRRT) is unknown. We employed an ex vivo CRRT model to characterize transmembrane clearance (CLTM) and derive optimal dosing regimens for patients su...
Impact of the double deletion ΔG242-T243 in KPC-2 in the effectiveness of ceftazidime-avibactam and imipenem-relebactam [0.03%] KPC-2中G242-T243双重缺失对阿维巴坦-头孢他啶和雷利巴坦-亚胺培南效果的影响
Florencia Brunetti,Gabriel Gutkind,Lin Gao et al. Florencia Brunetti et al.
Combinations of β-lactam-diazabicyclooctane inhibitors (DBOs) like ceftazidime-avibactam (CZA) and imipenem-relebactam (IMR) have shown efficacy in treating KPC-2-producing Klebsiella pneumoniae. However, CZA-resistant K. pneumoniae strain...
Determining an appropriate fosfomycin (ZTI-01) dosing regimen in pneumonia patients by utilizing minimal PBPK modeling and target attainment analysis [0.03%] 基于最小PBPK建模和靶标达成分析确定肺病患者使用fosfomycin（ZTI-01）的合适给药剂量方案
Jomana Al Hroot,Joshua Reeder,Xuanzhen Yuan et al. Jomana Al Hroot et al.
Fosfomycin, a broad-spectrum antibiotic used for uncomplicated cystitis, represents a potential promising candidate in combating resistant pneumonia. To facilitate the transition of fosfomycin to broader indications, including pneumonia, a ...
Population pharmacokinetics of intravenous fosfomycin: dose optimization for critically ill patients with and without kidney replacement therapy [0.03%] 静脉注射磷霉素的群体药代动力学：重症患者剂量优化（有无肾脏替代疗法）
Katharina M Götz,Sascha Kreuer,Anke-Katrin Volz et al. Katharina M Götz et al.
We investigated the pharmacokinetics (PK) of intravenous fosfomycin in critically ill patients undergoing different types of kidney replacement therapy (KRT) to identify optimized dosing regimens for patient care. Four prospective, observat...
Population pharmacokinetics and dosing optimization of teicoplanin in renal transplant patients [0.03%] 肾移植患者中替考拉宁的群体药代动力学及剂量优化研究
Yangang Zhou,Jiawei Peng,Ping Xu et al. Yangang Zhou et al.
The objectives of this study were to investigate the population pharmacokinetic (PK) characteristics of teicoplanin in renal transplant patients and to provide recommendations for optimal teicoplanin dosing regimens. A total of 99 renal tra...
Plasmodium falciparum Kelch-13 artemisinin partial resistance markers in Fort Portal, Western Uganda, 2024 [0.03%] 2024年乌干达西部福特portal恶性疟原虫Kelch-13基因突变与青蒿素部分耐药标志物关系研究
Welmoed van Loon,Emma Schallenberg,Emmanuel Mande et al. Welmoed van Loon et al.
In Fort Portal, Uganda, artemisinin resistance-associated mutations in Plasmodium falciparum Kelch13 (n = 126) were present in 4.8% (675V, 561H, and 441L). A mutation of unknown relevance, 490T, occurred in 9.5%. PfMDR1 variants suggested i...
Comparative effectiveness and safety of colistin-based versus high-dose ampicillin/sulbactam-based combination therapy for nosocomial pneumonia caused by carbapenem-resistant Acinetobacter baumannii [0.03%] 防治碳青霉烯类耐药不动杆菌院内感染所致肺炎的多粘菌素联合疗法与高剂量氨苄西林/舒巴坦联合疗法的效果和安全性比较研究
Jaehoon Lee,Imchang Lee,Ki-Byung Lee et al. Jaehoon Lee et al.
Differences exist between Infectious Diseases Society of America guidance and European Society of Clinical Microbiology and Infectious Diseases guidelines on treating pneumonia caused by carbapenem-resistant Acinetobacter baumannii (CRAB). ...